MDMA Pharmacokinetics
Investigator: Rudolf Brenneisen, PhD University of Bern, Switzerland Contact: br> Completed and published, just a few subjects. Also see the details and references section.
MDMA Neurotoxicity Study
Investigators: Una McCann, MD, George Ricaurte, MD, PhD Johns Hopkins University – Baltimore, Maryland Sponsor:NIH PET scan study, MDMA Neurotoxicity, MDMA Users vs. Control Group. MAPS Commentary …
Human Psychopharmacology of N,N-dimethyltryptamine
Investigator: Rick Strassman, MD University of New Mexico, USA Contact: Sponsor: NIDA Psychobiological study, finished and published. MAPS Bulletin – Volume 6 Number 1 Autumn 1995 University of New …
Ketamine Psychedelic Therapy in the Treatment of Alcoholics
Investigator: Evgeny Krupitsky, MD, PhD St. Petersburg, Russia Sponsor: Leningrad Regional Center for Alcoholism and Drug Addiction Therapy, MAPS Ten years of clinical studies completed and published. …
Psilocybins Effects on Cognition
Investigator: Manfred Spitzer, MD, PhD et al. Psychiatrische Universitats Klinic, Heidelberg, Germany Human clinical study, completed and published. More psilocybin research in Germany Spitzer M, et al. …
Human Psychopharmacology of Psilocybin
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …
Human Psychedelic Research: A Historical And Sociological Analysis
Human Psychedelic Research: A Historical And Sociological Analysis Undergraduate Thesis for the Degree of Bachelor of Arts in Natural Sciences (History and Philosophy of Science) by Luke Williams, April …
FY 1998 Financial Report
You can read this report in its original form here. MAPS IRS Form 990 for 1998 in PDF format Fiscal Year June 1, 1997 — May 31, 1998 (FY 97-98) was a strong year for MAPS with a combination of important …
The Concord Prison Experiment Experiment Follow-Up
Investigator: Rick Doblin, Ph.D. This study, originally published in the Journal of Psychoactive Drugs [Oct-Dec 1998] is one in a series of long-term follow-ups to early psychedelic research that MAPS …
FY 1997 Financial Report
You can read this report in its original form here. MAPS' income in FY 96-97 was $558,683. FY 96-97 represented a dramatic increase in income, expenditures and number of projects over FY 95- 96. FY …
NIH Workshop on the Medical Utility of Marijuana
MAPS report(Turning Protests into Protocols: Dr. Harter´s Legacy) to NIDA’s Expert Panel on Medical Marijuana Research – submitted February 25, 1997 following the February 19-20, 1997 …
After Proposition 200 and 215
December 2, 1996 Senate Judiciary Committee Hearing on Medical Marijuana – A message to new visitors of the MAPS website. MAPS Policy in Response to Prop. 200 and Prop. 215
